Table 5 Molecular markers of resistance for treatment failures observed during therapeutic efficacy monitoring in Angola, 2017
Marker | n (%) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Benguela | Zaire | Lunda Sul | ||||||||||||||
DP | ASAQ | AL | ASAQ | AL | ||||||||||||
Reinf day 0 | Reinf day failure | Reinf day 0 | Reinf day failure | Reinf day 0 | Reinf day failure | Recr day 0 | Recr day failure | Reinf day 0 | Reinf day failure | Recr day 0 | Recr day failure | Reinf day 0 | Reinf day failure | Recr day 0 | Recr day failure | |
n = 5 | n = 5 | n = 1 | n = 1 | n = 3 | n = 3 | n = 4 | n = 4 | n = 11 | n = 11 | n = 5 | n = 5 | n = 6 | n = 6 | n = 3 | n = 3 | |
pfk13 sequence | ||||||||||||||||
Wildtype | 5 (100) | 5 (100) | 1 (100) | 1 (100) | 2 (67) | 3 (100) | 4 (100) | 4 (100) | 11 (100) | 11 (100) | 5 (100) | 5 (100) | 6 (100) | 6 (100) | 3 (100) | 3 (100) |
A504V | – | – | – | – | 1 (33) | – | – | – | – | – | – | – | – | – | – | – |
pfcrt sequencea | ||||||||||||||||
CVMNK | 2 (40) | 4 (80) | – | – | 1 (33) | 3 (100) | 1 (25) | 3 (75) | 5 (45) | – | 2 (40) | – | 6 (100) | 5 (83) | 3 (100) | 3 (100) |
CVIET | 4 (80) | 1 (20) | 1 (100) | 1 (100) | 2 (67) | – | 3 (75) | 2 (50) | 7 (64) | 11 (100) | 5 (100) | 5 (100) | 1 (17) | 1 (17) | – | – |
pfmdr1 sequenceb | ||||||||||||||||
NYD | 4 (80) | 5 (100) | 1 (100) | 1 (100) | 3 (100) | 2 (67) | 4 (100) | 3 (75) | 5 (45) | 7 (64) | 4 (80) | 5 (100) | 6 (100) | 5 (83) | 2 (67) | 2 (67) |
NFD | 1 (20) | – | – | – | – | 1 (33) | – | 1 (25) | 6 (55) | 2 (18) | 1 (20) | – | – | 1 (17) | 2 (67) | 2 (67) |
YFD | – | – | – | – | – | – | – | – | – | 2 (18) | – | – | – | – | – | – |
pfmdr1 copy number | ||||||||||||||||
1 | 5 (100) | 5 (100) | 1 (100) | 1 (100) | 3 (100) | 3 (100) | 4 (100) | 4 (100) | 11 (100) | 11 (100) | 5 (100) | 5 (100) | 6 (100) | 6 (100) | 3 (100) | 3 (100) |
plasmepsin 2 copy number | ||||||||||||||||
1 | 5 (100) | 5 (100) | 1 (100) | 1 (100) | 3 (100) | 3 (100) | 4 (100) | 4 (100) | 11 (100) | 11 (100) | 5 (100) | 5 (100) | 6 (100) | 6 (100) | 3 (100) | 3 (100) |